TME PHARM.CONF.IPO EO 1- (0N6A) — Net Asset Momentum
TME PHARM.CONF.IPO EO 1- (0N6A) recorded a net asset momentum of -197.8% as of December 2025, with net assets of €-1.58 Million EUR. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See TME PHARM.CONF.IPO EO 1- (0N6A) net assets for net asset value and shareholders' equity analysis.
YoY Momentum
Current Net Assets
Years of Data
Country
TME PHARM.CONF.IPO EO 1- Net Asset Momentum (2021–2025)
This chart tracks TME PHARM.CONF.IPO EO 1-'s year-over-year net asset growth across 5 annual reporting periods from 2021 to 2025. The most recent momentum reading is -197.8%, with net assets of €-1.58 Million EUR as of December 2025. For live market cap and overall valuation, see TME PHARM.CONF.IPO EO 1- (0N6A) total market value.
Annual Net Asset History for TME PHARM.CONF.IPO EO 1- (2021–2025)
The table below shows the complete annual net asset history for TME PHARM.CONF.IPO EO 1- from 2021 to 2025, covering 5 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. Check how tangible is TME PHARM.CONF.IPO EO 1-'s equity to evaluate the tangible quality of the company's equity base.
| Year | Net Assets (EUR) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | €-1.58 Million | €2.14 Million | €3.72 Million | ▼ -197.8% |
| 2024 | €1.61 Million | €3.41 Million | €1.79 Million | ▲ +649.0% |
| 2023 | €-294.00K | €2.49 Million | €2.79 Million | ▲ +76.9% |
| 2022 | €-1.27 Million | €5.24 Million | €6.51 Million | ▼ -128.3% |
| 2021 | €4.50 Million | €9.77 Million | €5.27 Million | — |